This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
By This Author:
Page 2 of 593

ASCO '15 -- Bristol, Abbvie Immune-Boosting Drug Lowers Progression Risk in Multiple Myeloma

By Adam Feuerstein

Positive results from the new Bristol/Abbvie drug elotuzumab were featured in a media preview Wednesday ahead of the American Society of Clinical Oncology (ASCO) annual meeting.

05:09PM 05/13/15

Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts

By Adam Feuerstein

The American Society of Clinical Oncology has provided public access to 5,000 cancer drug trial research abstracts ahead of its big annual meeting. These will be some highlights for investors.

05:00PM 05/13/15

Vertex Pharma Cystic Fibrosis FDA Advisory Panel Live Blog

By Adam Feuerstein

A group of outside experts convened by the U.S. Food and Drug Administration is meeting Tuesday to review a new combination therapy for cystic fibrosis developed by Vertex Pharmaceuticals.

07:42AM 05/12/15

NewLink's Pancreatic Cancer Vaccine on Long Road to Study Failure

By Adam Feuerstein

The odds are now high that NewLink's HyperAcute pancreas vaccine will prove to be a failure once a final survival analysis is conducted later this year or in early 2016.

06:08AM 05/12/15

Five Reasons MannKind's Q1 Performance Rang Loud Alarm Bells

By Adam Feuerstein

MannKind's conference call on Friday morning didn't go well. Management admitted Afrezza's launch is slower than expected. Cash burn and debt remains problems which need to be addressed soon.

11:23AM 05/08/15

Fear of a 'Soliris Killer' Might Have Driven Alexion to Overpay for Synageva

By Adam Feuerstein

Investors see Alexion's willingness to write a huge check for Synageva as a tacit acknowledgment that Soliris' long-term future might be more at risk than the company lets on.

05:45AM 05/07/15

Alexion Pays Hefty $8.4 Billion to Acquire Synageva, Expand Rare Disease Drug Business

By Adam Feuerstein

The cash and stock deal values Synageva at $230 per share, based on Alexion's average closing price for the past nine days.

08:35AM 05/06/15

Amgen Indulges in Another Rheumatoid Arthritis Drug Price Increase

By Adam Feuerstein

The hike in Enbrel's list price pushed through by Amgen illustrates again how drug companies profit by raising the cost of their older medicines to offset falling prescription volume.

02:43PM 05/05/15

NewLink Insiders Sell Stock While Moss Grows on Pancreatic Cancer Vaccine Analysis

By Adam Feuerstein

The wait goes on for NewLink Genetics to disclose the second interim analysis from the ongoing phase III study of its pancreatic cancer vaccine.

10:40AM 05/05/15

Biotech Stock Mailbag: Biotech Bull So Insanely Good It Will Make You Forget Week's Pain

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

08:31AM 05/01/15

Page 2 of 593

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV


DOW 18,232.02 -53.72 -0.29%
S&P 500 2,126.06 -4.76 -0.22%
NASDAQ 5,089.3620 -1.4320 -0.03%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs